726 related articles for article (PubMed ID: 36117524)
1. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R; Galland L; Kalfeist L; Ghiringhelli F; Ladoire S; Limagne E
Oncoimmunology; 2022; 11(1):2120676. PubMed ID: 36117524
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic targeting of cancer-induced immunosuppressive cells.
Alizadeh D; Larmonier N
Cancer Res; 2014 May; 74(10):2663-8. PubMed ID: 24778417
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y; Yi M; Niu M; Mei Q; Wu K
Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
[TBL] [Abstract][Full Text] [Related]
4. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
5. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
6. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
7. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
8. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
11. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors.
Hou A; Hou K; Huang Q; Lei Y; Chen W
Front Immunol; 2020; 11():783. PubMed ID: 32508809
[TBL] [Abstract][Full Text] [Related]
12. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
Osipov A; Saung MT; Zheng L; Murphy AG
J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
14. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
Zhang Y; Guoqiang L; Sun M; Lu X
Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
17. Beyond Immunosuppression: The Multifaceted Functions of Tumor-Promoting Myeloid Cells in Breast Cancers.
Blaye C; Boyer T; Peyraud F; Domblides C; Larmonier N
Front Immunol; 2022; 13():838040. PubMed ID: 35309358
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y; Tang F; Wei YQ; Wei XW
J Hematol Oncol; 2022 May; 15(1):61. PubMed ID: 35585567
[TBL] [Abstract][Full Text] [Related]
19. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
20. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
